4.7 Review

Sulfonylureas for Treatment of Periodontitis-Diabetes Comorbidity-Related Complications: Killing Two Birds With One Stone

Journal

FRONTIERS IN PHARMACOLOGY
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.728458

Keywords

periodontitis-diabetes comorbidity; sulfonylureas; inflammation; bone metabolism; angiogenesis

Funding

  1. project of Guangzhou Science and Technology Bureau [202002030301]
  2. Department of Education of Guangdong Province [2018KTSCX186]
  3. highlevel university construction funding of Guangzhou Medical University [02-412-B205002-1003018, 02-410-B205001293, B185006003014, B195002003017, 02-412-B205002-1003017]

Ask authors/readers for more resources

Periodontitis is a prevalent oral inflammatory disease that can lead to tooth loss and oral health problems. It mainly affects periodontal tissue by affecting the host immune system and bone homeostasis. This disease is associated with various systemic diseases, including diabetes, which is another common inflammatory disease. Combining anti-inflammatory drugs with antibiotics may be a treatment option for periodontitis in patients with diabetes.
Periodontitis is one of the most prevalent oral inflammatory diseases leading to teeth loss and oral health problems in adults. Periodontitis mainly affects periodontal tissue by affecting the host immune system and bone homeostasis. Moreover, periodontitis is associated with various systemic diseases. Diabetes is a metabolic disease with systemic effects. Both periodontitis and diabetes are common inflammatory diseases, and comorbidity of two diseases is linked to exacerbation of the pathophysiology of both diseases. Since bacterial dysbiosis is mainly responsible for periodontitis, antibiotics are widely used drugs to treat periodontitis in clinics. However, the outcomes of antibiotic treatments in periodontitis are not satisfactory. Therefore, the application of anti-inflammatory drugs in combination with antibiotics could be a treatment option for periodontitis-diabetes comorbidity. Anti-diabetic drugs usually have anti-inflammatory properties and have shown beneficial effects on periodontitis. Sulfonylureas, insulin secretagogues, are the earliest and most widely used oral hypoglycemic drugs used for type-2 diabetes. Studies have found that sulfonylurea drugs can play a certain role in the mitigation of periodontitis and inflammation. This article reviews the effects of sulfonylurea drugs on the mitigation of periodontitis-diabetes comorbidity-related inflammation, bone loss, and vascular growth as well as the involved molecular mechanisms. We discuss the possibility of a new application of sulfonylureas (old drug) to treat periodontitis-diabetes comorbidity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available